Theriva Biologics issues 27,316 common shares upon conversion of Series C and D preferred stock

Theriva Biologics, Inc.

4,138 Series C shares converted into 1,086 common shares at $30.50 per share.
100,000 Series D shares converted into 26,230 common shares at $30.50 per share.
Total 27,316 common shares issued; no Series C or D preferred shares remain outstanding.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.